- ISIN
- US03168L1052
- CUSIP
- 03168L105
- Sector
- Healthcare
- IPO Date
- Jan 15, 2009
Highlights
- Market Cap
- $5.85B
- Enterprise Value
- $8.62B
- EPS (TTM)
- $0.48
- PE Ratio
- 37.97
- PEG Ratio
- 1.32
- Total Revenue (TTM)
- $3.12B
- Gross Profit (TTM)
- $1.23B
- EBITDA (TTM)
- $447.79M
- Year Range
- $7.80 - $19.26
- Target Price
- $18.67
- ROA (TTM)
- 4.17%
- ROE (TTM)
- 477.24%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $32.67M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AMRX Performance Chart
Amneal Pharmaceuticals, Inc. (AMRX) is up 45.4% since the beginning of the year. At $18 per share, AMRX is trading 4.9% below its 52-week high of $19. Investors who bought $1,000 worth of AMRX shares 5 years ago would now be looking at an investment worth $3,716.
Loading charts...
Compare this symbol against anything
Returns By Period
Amneal Pharmaceuticals, Inc. (AMRX) has returned 45.40% so far this year and 133.97% over the past 12 months. Over the last ten years, AMRX has returned -5.11% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Amneal Pharmaceuticals, Inc.
- 1D
- -0.97%
- 1M
- 6.82%
- 6M
- 33.92%
- YTD
- 45.40%
- 1Y
- 133.97%
- 3Y*
- 79.45%
- 5Y*
- 30.02%
- 10Y*
- -5.11%
- ALL TIME*
- 11.78%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AMRX Monthly Returns History
Based on dividend-adjusted daily data since Jan 15, 2009, AMRX's average daily return is +0.12%, while the average monthly return is +2.05%. At this rate, an investment would double in approximately 2.8 years.
Historically, 54% of months were positive and 46% were negative. The best month was Jan 2009 with a return of +72.3%, while the worst month was Jul 2019 at -49.0%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.
On a daily basis, AMRX closed higher 49% of trading days. The best single day was Jan 15, 2009 with a return of +82.7%, while the worst single day was Jul 10, 2019 at -36.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.57% | 0.95% | -9.99% | 3.54% | 2.33% | 31.44% | 5.83% | 45.40% | |||||
| 2025 | 4.29% | 4.96% | -3.34% | -8.59% | -4.44% | 10.52% | -3.34% | 22.25% | 4.71% | 8.09% | 15.71% | 0.64% | 59.09% |
| 2024 | -11.86% | 3.18% | 9.78% | -0.17% | 10.41% | -4.94% | 15.43% | 18.14% | -3.93% | 1.80% | -2.36% | -4.23% | 30.48% |
| 2023 | 10.55% | -6.36% | -32.52% | 38.85% | 21.24% | 32.48% | 3.23% | 27.81% | 3.18% | -8.29% | 11.37% | 40.84% | 205.03% |
| 2022 | -7.52% | 2.26% | -7.95% | -7.43% | -5.96% | -12.40% | 11.32% | -38.70% | -6.91% | 8.91% | 16.36% | -22.27% | -58.46% |
| 2021 | 5.25% | 12.06% | 24.86% | -18.13% | 2.72% | -9.54% | -3.71% | 14.40% | -5.32% | 2.81% | -23.86% | 14.59% | 4.81% |
Benchmark Metrics
Amneal Pharmaceuticals, Inc. has an annualized alpha of 15.48%, beta of 1.04, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since January 15, 2009.
- This stock participated in 135.84% of S&P 500 Index downside but only 126.12% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.48%
- Beta
- 1.04
- R²
- 0.09
- Upside Capture
- 126.12%
- Downside Capture
- 135.84%
Return for Risk
Risk / Return Rank
AMRX ranks 97 for risk / return — above 97% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AMRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.66 | ||
| Sortino ratioReturn per unit of downside risk | +2.69 | ||
| Omega ratioGain probability vs. loss probability | 1.58 | 1.25 | +0.33 |
| Calmar ratioReturn relative to maximum drawdown | 6.07 | 2.00 | +4.07 |
| Martin ratioReturn relative to average drawdown | 15.13 | 8.49 | +6.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Amneal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amneal Pharmaceuticals, Inc. was 97.52%, occurring on Mar 28, 2023. The portfolio has not yet recovered.
The current Amneal Pharmaceuticals, Inc. drawdown is 64.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.52%Mar 2023 | 7y 11mo | — | 11y 3moApr 2015 - now | — |
-48.49%Mar 2013 | 1y 9mo | 1y 3mo | 3y 27dMay 2011 - Jun 2014 | — |
-36.82%Apr 2009 | 1mo 13d | 3mo 17d | 5moFeb 2009 - Jul 2009 | Financial crisis2007–2009 |
-27.71%Aug 2010 | 2mo 16d | 1mo 13d | 3mo 29dJun 2010 - Oct 2010 | — |
-25.93%Aug 2014 | 1mo 3d | 3mo 18d | 4mo 21dJul 2014 - Nov 2014 | — |
Drawdown Indicators
| AMRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.52% | -56.78% | -40.74% |
Max Drawdown (1Y)Largest decline over 1 year | -22.25% | -9.10% | -13.15% |
Max Drawdown (3Y)Largest decline over 3 years | -26.80% | -18.90% | -7.90% |
Max Drawdown (5Y)Largest decline over 5 years | -78.29% | -25.43% | -52.86% |
Max Drawdown (10Y)Largest decline over 10 years | -95.93% | -33.92% | -62.01% |
Current DrawdownCurrent decline from peak | -64.30% | -1.58% | -62.72% |
Average DrawdownAverage peak-to-trough decline | -54.42% | -10.70% | -43.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.91% | 2.14% | +6.77% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Amneal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Amneal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AMRX, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMRX has a P/E ratio of 38.0. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AMRX compared to other companies in the Drug Manufacturers - Specialty & Generic industry. AMRX currently has a PEG ratio of 1.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AMRX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMRX has a P/S ratio of 1.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AMRX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMRX has a P/B value of 182.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AMRX
Add Amneal Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AMRX